{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-082307","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.015985+00:00","generated_at":"2026-05-31T22:37:02.107760+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024","bullets":["Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.","Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.","Primary endpoint: mean % change from baseline in EASI score at week 14.","SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.","CEO cites patient demand as driver of enrollment surpassing initial target."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-082307","json":"https://secwatch.observer/filing/0000950170-24-082307.json","markdown":"https://secwatch.observer/filing/0000950170-24-082307.md","text":"https://secwatch.observer/filing/0000950170-24-082307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/0000950170-24-082307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/qttb-20240709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:37:02.107760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}